Cellectis SA

CLLS.US
Healthcare · Biotechnology
2.84
-0.05 (-1.73%)
USD · NASDAQ

Company Information

Company Name
Cellectis SA
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US15117K1034
CIK: 0001627281
CUSIP: 15117K103
Currency: USD
Full Time Employees: 224
Phone: 33 1 81 69 16 00
Fiscal Year End: December
IPO Date: Feb 07, 2007
Description:

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Address:

8, rue de la Croix Jarry, Paris, France, 75013

People

Directors & Officers

Name Title Year Born
Dr. Andre Choulika Ph.D. Co-Founder, CEO & Director 1965
Dr. David J. Sourdive Ph.D. Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director 1967
Mr. Arthur Stril CFO & Chief Business Officer 1989
Valerie Cros Principal Financial Officer & Principal Accounting Officer NA
Mr. Jean Charles Epinat Ph.D. Chief Technological Officer NA
Dr. Philippe Duchateau Ph.D. Chief Scientific Officer 1963
Ms. Marie-Bleuenn Terrier General Counsel & Secretary of the Board of Directors 1982
Pascalyne Wilson Director of Communications NA
Ms. Kyung Nam-Wortman Executive VP & Chief Human Resources Officer 1970
Mr. Stephan Reynier M.Sc. Chief Regulatory & Pharmaceutical Compliance Officer 1969

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
B Group, Inc 3.28M Mar 31, 2026 3.26% $7.71 0.00%
UBS Asset Mgmt Americas Inc 3.18M Mar 31, 2026 3.16% $0.00 0.00%
Long Focus Capital Management, LLC 2.74M Mar 31, 2026 2.73% $0.23 -1.57%
BlackRock Inc 341.52K Mar 31, 2026 0.34% $0.00 -11.13%
Delaware Management Holdings Inc 226.88K Mar 31, 2026 0.23% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 86.78K Mar 31, 2026 0.09% $0.00 -0.46%
LPL Financial Corp 84.35K Mar 31, 2026 0.08% $0.00 -0.53%
Susquehanna International Group, LLP 65.94K Mar 31, 2026 0.07% $0.00 25.79%
Citadel Advisors Llc 44.32K Mar 31, 2026 0.04% $0.00 -53.56%
Marshall Wace Asset Management Ltd 41.11K Mar 31, 2026 0.04% $0.00 -76.96%
BNP Paribas Arbitrage, SA 41.00K Mar 31, 2026 0.04% $0.00 -0.73%
UBS Group AG 29.77K Mar 31, 2026 0.03% $0.00 -40.57%
Delaney Dennis R 24.00K Mar 31, 2026 0.02% $0.03 0.00%
XTX Topco Ltd 16.27K Mar 31, 2026 0.02% $0.00 0.00%
Rhumbline Advisers 15.09K Mar 31, 2026 0.02% $0.00 13.06%
Lido Advisors, LLC 10.09K Mar 31, 2026 0.01% $0.00 0.00%
Global Retirement Partners, LLC. 7.04K Dec 31, 2025 0.01% $0.00 0.00%
HARBOUR INVESTMENTS, INC. 4.50K Mar 31, 2026 0.00% $0.00 0.00%
NATIONAL BANK OF CANADA /FI/ 3.60K Mar 31, 2026 0.00% $0.00 0.00%
Wells Fargo & Co 3.15K Mar 31, 2026 0.00% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 UBS Lux Dgtl Hlth Eq Fd seeding P acc 1.30M 1.30% ▲ 0.00% Mar 31, 2026
2 Nomura Healthcare Fund Class I 226.88K 0.23% ▲ 0.00% May 31, 2026
3 Galileo - Biotech Innovation Fund S USD 226.07K 0.22% ▲ 0.00% Dec 31, 2025
4 iShares Biotechnology ETF 225.44K 0.22% ▲ 1.04% Jun 30, 2026
5 Ox Capital Dynamic Asia N USD Unhdgd Acc 95.29K 0.09% ▲ 0.00% Jan 31, 2026
6 Prisma Cube 30.00K 0.03% ▲ 0.00% Mar 31, 2026
7 P & S Renditefonds T 15.00K 0.01% ▲ 0.00% Apr 30, 2026

Financial Highlights

Market Cap: $291.02M
EBITDA: $-32.75M
PEG Ratio: $0.00
Book Value: $0.83
Earnings/Share: $-0.67
Profit Margin: -89.51%
Operating Margin: -333.43%
ROA (TTM): -8.43%
ROE (TTM): -76.34%
Revenue (TTM): $75.11M
Revenue/Share (TTM): $0.75
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -37.30%

Valuation Metrics

Enterprise Value: $197.78M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 72.70M
Shares Float: 46.69M
% Insiders: 0.00%
% Institutions: 1,653.90%
Short % Float: 0.53%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$72.95M
Cost of Goods Sold
adjust
$-9.80M
Gross Profit
subtotal
$63.15M
SG&A
adjust
$-8.60M
R&D
adjust
$-93.52M
Operating Income
subtotal
$-33.08M
Other / Non-Operating Items
adjust
$-34.52M
Net Income
subtotal
$-67.59M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CLLS.US!